DOI/DOC
Shaping the Future of Psychedelic Policy at Harvard Law School
This month, Students for Sensible Drug Policy (SSDP) joined leading thinkers in psychedelic law, policy, science, and ethics for Psychedelics Bootcamp 2025 at Harvard Law School. Organized by the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics, in partnership with the Project on Psychedelics Law and Regulation (POPLAR), this two-day intensive brought together a dynamic group of students, scholars,
ON WORLD PSYCHEDELICS DAY, DEA ATTEMPTS TO SILENCE SCIENCE BY RECOMMENDING TO SCHEDULE DOI AND DOC
FOR IMMEDIATE RELEASE Contact: Gina Giorgio Director of Strategy and Development Students for Sensible Drug Policy gina@ssdp.org ON WORLD PSYCHEDELICS DAY, DEA ATTEMPTS TO SILENCE SCIENCE BY RECOMMENDING TO SCHEDULE DOI AND DOC By recommending that 2,5-dimethoxy-4-iodo-amphetamine (DOI) and 2,5-dimethoxy-4-chloro-amphetamine (DOC) be added to Schedule I of the Controlled Substances Act, the Administrative Law Judge is supporting the DEA’s proposal
Fight for your right to research – Boulder Weekly
Gina Giorgio, Director of Strategy and Development at Students for Sensible Drug Policy, wrote an op-ed in Boulder Weekly discussing our historic court case with the DEA defending the scheduling status of niche research chemicals DOI & DOC to protect psychedelic research. “None of us were experts on administrative hearings, we were just a couple of passionate scientists who wanted
BREAKING: Nonprofit Representing Psychedelic Researchers Files Post-Trial Brief Following Historic Hearing
Contact: Gina Giorgio Director of Strategy and Development Students for Sensible Drug Policy gina@ssdp.org BREAKING: NONPROFIT REPRESENTING PSYCHEDELIC RESEARCHERS FILES POST-TRIAL BRIEF FOLLOWING HISTORIC HEARING TO KEEP SCIENTIFIC RESEARCH LEGAL Setting a Powerful Precedent: Research Harm Takes Center Stage for the First Time in DEA Scheduling Case [Arlington, VA, January 6th, 2025] – Students for Sensible Drug Policy (SSDP) has filed its post-trial brief
We Fought the DEA in Their Own Court — For Science!
This article was written by Written by:Alaina M. Jaster, PhD Postdoctoral Scholar, Wayne State University Co-founder, Psychedelic Brain Science Podcast Member, SSDP Science Policy Committee Elijah Z. Ullman, PhD Post-doctoral Research Fellow | Emory University Chair, SSDP Science Policy Committee The second floor of a generally unassuming building was full of activity on average Tuesday, as the SSDP/Ramos team went
SSDP Kicks off DEA Court Hearing with Press Conference in Arlington, Virginia
This morning in front of the Drug Enforcement Administration (DEA) Headquarters in Arlington, Virginia, SSDP’s Science Policy Committee, a group of PhD students and other researchers who are fighting back against the War on Drugs, along with SSDP’s legal team spoke about our unprecedented court hearing kicking off today and running through November 25. You can watch the press conference
SSDP’s Historic Court Case with DEA Featured in Cannabis Law Report
We are thankful to Cannabis Law Report for sharing updating on our historic court case with the DEA beginning November 12th in Arlington, Virginia at the DEA Administrative Court. Scheduling DOI and DOC would create serious impediments to potentially life-saving research, and yet SSDP is the only drug policy organization currently fighting to keep DOI and DOC off the Controlled
SSDP Science Policy Committee successfully pushes back on DEA effort to criminalize psychedelic research
FOR IMMEDIATE RELEASE: SSDP Science Policy Committee successfully pushes back on DEA effort to criminalize psychedelic research On Friday August 26, 2022, the Drug Enforcement Administration (DEA) withdrew proposed Schedule I status for 2,5-dimethoxy-4-iodoamphetamine (DOI) and 2,5-dimethoxy-4-chloroamphetamine (DOC). The notice states that “The Drug Enforcement Administration (DEA) is withdrawing a proposed rule that was published in the Federal Register on
DEA SILENCES SCIENTISTS; STUDENT GROUP PUSHES BACK AGAIN
Contact:Gina Giorgio Director of Strategy and DevelopmentStudents for Sensible Drug Policygina@ssdp.org DEA SILENCES SCIENTISTS; STUDENT GROUP PUSHES BACK AGAIN Since 2022, Students for Sensible Drug Policy (SSDP) Has Led the Fight to Prevent the DEA From Scheduling DOI and DOC, Which Would Create Serious Impediments to Potentially Life-Saving Research [Washington D.C., October 3, 2024] — Students for Sensible Drug Policy (SSDP)—a
DEA SCHEDULES FIRST-EVER TWO WEEK PUBLIC HEARING ON PSYCHEDELICS
Contact:Gina Giorgio Director of Strategy and DevelopmentStudents for Sensible Drug Policygina@ssdp.org DEA SCHEDULES FIRST-EVER TWO WEEK PUBLIC HEARING ON PSYCHEDELICS IN ONGOING STUDENT-LED EFFORT TO PREVENT THE WRONGFUL SCHEDULING OF VITAL RESEARCH CHEMICALS WITH PROMISING MEDICAL POTENTIAL Since 2022, Students for Sensible Drug Policy (SSDP) Has Led the Fight to Prevent the DEA From Scheduling DOI and DOC, Which Would Create
STUDENT-LED NONPROFIT FIGHTS THE DEA IN COURT IN EFFORT TO PRESERVE ACCESS TO VITAL RESEARCH CHEMICALS WITH PROMISING MEDICAL POTENTIAL
Students for Sensible Drug Policy (SSDP) is the Only Drug Policy Organization Actively Working to Prevent the DEA From Scheduling DOI and DOC, Which Would Create Serious Impediments to Potentially Life-Saving Research
SSDP FIGHTS THE DEA IN COURT TO PRESERVE RESEARCH CHEMICALS
Contact:Kat MurtiExecutive DirectorStudents for Sensible Drug Policykat@ssdp.org STUDENT-LED NONPROFIT FIGHTS THE DEA IN COURT IN EFFORT TO PRESERVE ACCESS TO VITAL RESEARCH CHEMICALS WITH PROMISING MEDICAL POTENTIAL Students for Sensible Drug Policy (SSDP) is the Only Drug Policy Organization Actively Working to Prevent the DEA From Scheduling DOI and DOC, Which Would Create Serious Impediments to Potentially Life-Saving Research [Washington
